Introduction {#s1}
============

The neurotransmitter norepinephrine (NE) has been implicated in several neuropsychiatric disorders. Many currently-used treatments for depression and attention deficit/hyperactivity disorder are based on modulation of synaptic availability of NE, as both classical tricyclic antidepressants and selective NE transporter (NET) inhibitors act by inhibiting the reuptake of NE into presynaptic nerve terminals, and thus increase its concentration in the synapse. Direct measurement of changes in synaptic NE concentrations in the human brain, using microdialysis, is invasive and impractical.

Positron emission tomography (PET) is a relatively non-invasive technique that has, in some cases, been applied to investigate changes in synaptic neurotransmitter concentrations in the living human brain. In the 1990s, it was already demonstrated that receptor binding of dopamine (DA) D~2~ receptor radioligands can be reduced by 10--30% by amphetamine-induced elevations of synaptic DA concentrations in human subjects ([@CIT0026]; [@CIT0005]). This application of PET has provided an important understanding of the role of synaptic DA in drug actions ([@CIT0044]; [@CIT0006]), in normal neuropsychology (see for review [@CIT0011]), as well as in the pathophysiology of addiction ([@CIT0047]), schizophrenia ([@CIT0027]), and Parkinson's disease ([@CIT0032]). Recently, encouraging progress has been reported for similar approaches targeted to synaptic serotonin ([@CIT0013]) and glutamate ([@CIT0031]) concentrations, but PET measurement of synaptic NE has so far remained unexplored in primates.

In comparison to monitoring of synaptic DA with \[^11^C\]raclopride, attempts to assess synaptic NE in the brain with PET are complicated by the multitude of adrenoceptor (AR) subtypes present in the mammalian brain. Almost all of the nine AR subtypes are known to be expressed in the central nervous system of humans and other mammals, with different anatomical distributions and variable expression levels. It is not obvious which AR subtype would be the best candidate for purposes of PET imaging. So far, most experience has been gained from attempts to target α~2~-ARs in the brain ([@CIT0019]; [@CIT0021]; [@CIT0041]; [@CIT0045]), compared to α~1~-ARs ([@CIT0003]) and β-ARs ([@CIT0046]). Application of α~2~-AR antagonist radioligands for measurement of changes in synaptic NE concentrations has recently been pioneered in pigs ([@CIT0024]). The subtype non-selective α~2~-AR antagonist yohimbine was labeled with ^11^C for PET imaging, and *d*-amphetamine (10mg/kg) was administered to elevate synaptic NE concentrations. Distribution volumes were reduced by 20--30% in several brain regions known to express α~2~-ARs, including the thalamus, cerebral cortex, the caudate nucleus, and cerebellum ([@CIT0024]).

Two limitations of the α~2~-AR radioligands evaluated so far are that they lack selectivity for α~2~-AR subtypes and have not been applied in primates. Of the three mammalian α~2~-AR subtypes, two (α~2A~-AR and α~2C~-AR) have widespread expression in the brain ([@CIT0036]; [@CIT0012]). α~2C~-ARs are mainly located in the basal ganglia, in contrast with α~2A~-ARs that are more widely distributed throughout the brain ([@CIT0036]; [@CIT0015]; [@CIT0012]). Recently, [@CIT0002] described the radiosynthesis of a novel α~2C~-AR selective antagonist radioligand \[^11^C\]ORM-13070 (*K* ~i~ = 0.6nM) and validated the tracer by *ex vivo* receptor binding studies in α~2A~- and α~2AC~-AR knockout mice, demonstrating that \[^11^C\]ORM-13070 provides selective and specific binding to α~2C~-ARs in the striatum and olfactory tubercle. In a subsequent first-in-man study, \[^11^C\]ORM-13070 was evaluated for its suitability as a radioligand for quantitative imaging of α~2C~-ARs in the human brain. It was suggested that striatal \[^11^C\]ORM-13070 receptor binding is sufficient for quantitation in human subjects and that the cerebellum is a suitable reference region for data analysis ([@CIT0500]; [@CIT0029]).

In the current study, we explored the suitability of \[^11^C\]ORM-13070 for measurement of acute changes in synaptic NE concentrations. We used amphetamine to stimulate NE release in the brain and to elevate its synaptic concentrations in rats and in non-human primates. Microdialysis experiments were performed to relate the observed changes in \[^11^C\]ORM-13070 binding to the amphetamine-induced elevations in synaptic NE and DA concentrations.

Materials and Methods {#s2}
=====================

Preparation of \[^11^C\]ORM-13070 {#s3}
---------------------------------

The reference compound ORM-13070 (1-\[(*S*)-1-(2,3-dihydrobenzo\[1,4\]dioxin-2-yl)methyl\]-4-(3-methoxymethylpyridin-2-yl)-piperazine) and its *O*-desmethyl precursor (ORM-13333) were provided by Orion Pharma. All other chemicals were obtained from commercial sources. The radiopharmaceutical procedures were performed as described earlier ([@CIT0002]).

Receptor Autoradiography {#s4}
------------------------

Autoradiographic receptor binding experiments were performed using \[^11^C\]ORM-13070 and cryosections of cynomolgus monkey (*Macaca fascicularis*) and human brains (source: Department of Forensic Medicine, Semmelweis Medical University, Budapest, Hungary; ethical approval: Semmelweis University Human Ethical Committee, no. 113/1995, 180/2001), following established protocols ([@CIT0016]). Non-specific binding was determined by co-incubation with the subtype non-selective α~2~-AR antagonist atipamezole (10 µM). Radioactivity was detected with a phosphorimager (BAS-5000, Fuji Photo Film Co.).

*Ex Vivo* Binding in Rats {#s5}
-------------------------

*Ex vivo* experiments in rats were approved by the Animal Experiment Board of the Province of Southern Finland. Animal care complied with the guidelines of the International Council of Laboratory Animal Science (ICLAS).

Ten male Sprague-Dawley rats (weighing 298±23g, mean ± standard deviation) were pretreated (subcutaneous \[s.c.\], 1mL/kg) with either vehicle (saline, *n* = 5) or *d*-amphetamine sulphate (0.3mg/kg as the free base, *n* = 5; Sigma Aldrich). Fifteen min later, they were sedated by inhalation of isoflurane (3--4%) and cannulated. Approximately 20min after the vehicle or amphetamine injection, \[^11^C\]ORM-13070 was injected into a tail vein at doses ranging from 70 MBq to 99 MBq (86±10 MBq; 400--850 μL, corresponding to molecular masses of 44--353ng of ORM-13070) under 2% isoflurane anesthesia. At 30min post injection of \[^11^C\]ORM-13070, the rats were sacrificed by cardiac puncture. Their brains were frozen and 40 μm cryosections were cut, thaw-mounted onto glass slides, and immediately opposed to imaging plates (BAS-TR2025, Fuji) for at least 40min.

The imaging plates were scanned with a Fuji BAS-5000 Analyzer and analyzed for count densities (photon-stimulated luminescence per unit area, PSL/mm^2^) using the Aida 2D densitometry program (Raytest Isotopenmessgeräte GmbH). Regions of interest were drawn for the olfactory tubercle, striatum (including the caudate and putamen) and cerebellum (cerebellar cortex). The cerebellum is known to have a negligible density of α~2C~-ARs, and was here used to estimate the free and non-specifically bound radioligand concentration in the brain. The binding of \[^11^C\]ORM-13070 was quantified using specific binding ratios (SBRs), obtained by first subtracting the cerebellum pixel density from the regional pixel density and then dividing the result with the cerebellum pixel density. The SBRs of the vehicle and amphetamine pretreatment groups were compared using two-tailed *t*-tests.

PET Measurements in Monkeys {#s6}
---------------------------

Experiments with non-human primates were approved by the Animal Research Ethical Committee of the Northern Stockholm region, and were performed according to the ''Guide for the Care and Use of Laboratory Animals'' ([@CIT0009]). Four adult cynomolgus monkeys (three females and one male), weighing 4.0--6.2kg, were included in the study. PET measurements were conducted with a High Resolution Research Tomograph (Siemens Molecular Imaging), and were performed under sevoflurane anesthesia using previously described protocols ([@CIT0014]).

In each PET measurement, a sterile phosphate buffered saline (PBS, pH = 7.4) solution containing 153±4 MBq (range: 148--160 MBq) \[^11^C\]ORM-13070 was injected as a bolus into a sural vein during five seconds with the simultaneous start of PET data acquisition. The average specific radioactivity at the time of injection of \[^11^C\]ORM-13070 was 569 GBq/μmol (range: 186--1104 GBq/μmol), corresponding to a mean injected mass of 0.12 μg (range: 0.05--0.28 μg) per injection. The radiochemical purity of \[^11^C\]ORM-13070 always exceeded 98%.

### Study Design {#s7}

A total of 20 PET measurements were performed on nine experimental days. The PET measurements were conducted two and an half hours apart. First, experiments were conducted to test the receptor specificity of \[^11^C\]ORM-13070 binding. On two days, a baseline PET measurement with \[^11^C\]ORM-13070 was followed by two PET measurements preceded by escalating doses of atipamezole. Atipamezole was infused i.v. over 15min, starting 25min before the \[^11^C\]ORM-13070 injection. The examined doses of atipamezole were 2.5 and 10 μg/kg on one day (NHP1) and 50 and 500 μg/kg on another day (NHP2). Atipamezole hydrochloride (Orion Pharma) was diluted with saline and the reported doses refer to the salt.

A second set of PET examinations was performed to evaluate the sensitivity of \[^11^C\]ORM-13070 binding to changes in synaptic NE concentrations. On four experimental days, a baseline PET measurement with \[^11^C\]ORM-13070 was followed by a measurement after pretreatment with amphetamine (0.5 or 1.0mg/kg as salt; NHP1--3). Dextroamphetamine sulphate (Apoteket) was formulated in PBS and was infused i.v. over 15min, starting 25min before the \[^11^C\]ORM-13070 injection. On another two experimental days, baseline PET measurements with \[^11^C\]ORM-13070 were followed by measurements after pretreatment with atomoxetine (0.3mg/kg as free base; NHP1 and NHP3). Atomoxetine (tomoxetine hydrochloride; Tocris) was formulated in saline and was infused i.v. using a high dose continuous pseudo-steady-state infusion protocol until the end of the PET measurement, starting 60min before the \[^11^C\]ORM-13070 injection (Seneca, [@CIT0038]; [@CIT0043]). On one final experimental day, two control baseline PET measurements were performed (NHP4). ([Table 1](#T1){ref-type="table"}).

### Plasma Radiometabolite Analysis {#s8}

Venous blood samples were collected at 4, 15, 30, 45, and 60min after i.v. injection of \[^11^C\]ORM-13070. Plasma radioactivity concentrations were determined in a well counter. The proportions of unchanged \[^11^C\]ORM-13070 and radioactive metabolites in plasma were determined with high-performance liquid chromatography (HPLC) ([@CIT0017]; [@CIT0002]).

### PET Quantitation {#s9}

Regional time-radioactivity curves were generated with individual template magnetic resonance images ([@CIT0014]). Specific receptor binding was defined as the difference between the total radioactivity concentration in the striatum and cerebellum. *BP* ~ND~ estimates were calculated with the simplified reference tissue model (SRTM; with time interval 0--33min; [@CIT0023]) and the interval method (with time interval of 4--33min; [@CIT0020]) with the cerebellum as reference region. Surrogate distribution volumes (*V* ~T\ AUC~) were calculated using the area under the regional time-radioactivity curve (4--63min) divided by the area under the curve of the venous plasma concentration of \[^11^C\]ORM-13070 (4--60min).

### Determination of Atipamezole and Atomoxetine Concentrations {#s10}

Blood samples were collected before (5min) and during (20, 40, and 60min) the PET measurements for determination of concentrations of atipamezole and atomoxetine in plasma. Analysis was with HPLC coupled to tandem mass spectrometry detection, using an API4000 Q Trap^TM^ tandem mass spectrometer equipped with an atmospheric pressure Turbo V^TM^ ion source (AB SCIEX). For both analytes, the lower limit of quantitation was 1ng/mL, and the intra-assay CV was \<10%.

Rat Brain Microdialysis {#s11}
-----------------------

All procedures were in accordance with the Pfizer Laboratory Animal Care Program and were approved by the Institutional Animal Care and Use Committee of Pfizer Global Research and Development. Rats were individually housed, had free access to food and water, and were maintained on a 12:12h light/dark cycle. *In vivo* microdialysis was performed essentially as described before ([@CIT0033]). Briefly, microdialysis guide cannulae were implanted above the striatum (AP +0.2mm, ML +3.2mm, DV -3.5mm from bregma) of isoflurane-anesthetized adult male Sprague-Dawley rats (Charles River). One day after surgery, microdialysis probes (BR-4, Bioanalytical Systems Inc.; 4mm polyacrylonitrile membrane) were inserted and perfused with artificial cerebrospinal fluid at 0.3 μL/min overnight. On the day of the experiment, probes were perfused at 2 μL/min and dialysate samples were collected in 30min fractions. After baseline sampling (3 x 30min), rats were dosed s.c. with *d*-amphetamine sulphate (0.3mg/kg as the free base, *n* = 6) or vehicle (saline, 2mL/kg, *n* = 4) in experiment 1 or i.p. with atomoxetine hydrochloride (1mg/kg as the free base, *n* = 5) or vehicle (saline, 2mL/kg, *n* = 5) in experiment 2, and samples were collected for another 3h. In order to evaluate the possible impact of isoflurane anesthesia on the PET study results, as part of experiment 1, after collection of the three baseline samples, one group of rats was anesthetized with isoflurane (3.5%) and anesthesia was maintained with 2% isoflurane for the remainder of the experiment. New baseline samples were collected under anesthesia, and the rats were then dosed with amphetamine (*n* = 8) or vehicle (*n* = 6) as indicated above. Concentrations of NE and DA in the dialysate samples were measured using HPLC with electrochemical detection ([@CIT0033]).

### Data Analysis {#s12}

The effect of anesthesia on basal concentrations of NE and DA was determined by comparing results from anesthetized rats to those from freely-moving animals using Mann-Whitney's U test. The effects of the drug treatments were determined by normalizing all NE and DA concentration data to baseline. Repeated measures analysis of variance (main effects: time and treatment) was employed to compare the drug treatments with vehicle treatment.

*In Vitro* Receptor Binding {#s13}
---------------------------

The binding affinity of amphetamine, atipamezole, and atomoxetine to human α~2A~-, α~2B~-, and α~2C~-ARs was determined with transfected Chinese hamster ovary cells and the α~2~-AR antagonist radioligand \[ethyl-^3^H\]RS79948-197 (0.3nM; Amersham Biosciences), as described previously ([@CIT0028]).

Results {#s14}
=======

Receptor Autoradiography {#s15}
------------------------

In cryosections of monkey and human brain, the binding of \[^11^C\]ORM-13070 was highest in the striatum, both in the caudate nucleus and the putamen, and low in the cerebellum. The striatal binding of \[^11^C\]ORM-13070 was blocked by co-incubation with the subtype non-selective α~2~-AR antagonist atipamezole (10 µM; [Figure 1A](#F1){ref-type="fig"} and [B](#F1){ref-type="fig"}).

![Representative whole-hemisphere autoradiograms showing the distribution of \[^11^C\]ORM-13070 binding to sagittal sections of a monkey brain (A), coronal sections of a human brain (B), and coronal sections of two rat brains (C). The rat sections were obtained from animals euthanized 30min post \[^11^C\]ORM-13070 injection. Amphetamine ('Amph', 0.3mg/kg subcutaneous \[s.c.\], 20min before i.v. injection of \[^11^C\]ORM-13070) tended to reduce the specific binding ratios (mean ± standard deviation, *n* = 5) in the olfactory tubercle (OT) and striatum (STR) of rats (D). In the primate brain sections, specific binding was demonstrated by co-incubation with a 10 µM concentration of the subtype non-selective α~2~-adrenoceptor antagonist atipamezole. SBR, specific binding ratio.](ijnppy_pyu081_f0001){#F1}

*Ex Vivo* Binding in Rats {#s16}
-------------------------

Thirty min after i.v. injection of \[^11^C\]ORM-13070, the radioactivity concentration was high in the olfactory tubercle and striatum of rats and low in the cerebellum ([Figure 1C](#F1){ref-type="fig"}). Following pretreatment with vehicle (*n* = 5), the SBRs were 2.2±0.3 for the olfactory tubercle and 1.4±0.3 for the striatum ([Figure 1D](#F1){ref-type="fig"}). After amphetamine pretreatment (*n* = 5), the SBRs were 1.7±0.3 for the olfactory tubercle and 1.2±0.2 for the striatum, indicating reductions in radioligand binding, but statistical significance was not reached for the effect of amphetamine on SBRs (-19%, *p* = 0.07 for the olfactory tubercle; -20%, *p* = 0.10 for the striatum; [Figure 1D](#F1){ref-type="fig"}).

PET Measurements in Monkey {#s17}
--------------------------

After i.v. injection of \[^11^C\]ORM-13070 in monkey, the radioactivity concentration was high in the striatum and low in the cerebellum ([Figure 2A](#F2){ref-type="fig"} and [B](#F2){ref-type="fig"}). Using the cerebellum as a reference region, the peak in striatal specific binding was observed after 10--15min. Regional time activity curves were fitted using the SRTM. Striatal *BP* ~ND~ values estimated using only the first 33min of the PET acquisition data were in good agreement with longer, 63min data collection. Striatal *BP* ~ND~ values estimated with the SRTM also agreed well with corresponding values obtained with the interval method ([Figure 2C](#F2){ref-type="fig"}). Radiometabolite analysis of monkey plasma demonstrated the presence of significant amounts of radioactivity in two distinct metabolite fractions (termed M1 and M2 with t~R~ of 2.6min and 4.3min, respectively), both more polar than the parent \[^11^C\]ORM-13070 (t~R~ = 8.2min; [Figure 2D](#F2){ref-type="fig"}). The proportion of intact \[^11^C\]ORM-13070 decreased over time from 66±7% at 4min to 24±3% at 60min (*n* = 9).

![Evaluation of the utility of \[^11^C\]ORM-13070 as a positron emission tomography (PET) tracer in cynomolgus monkeys. (A) PET summation images represent mean radioactivity levels in time frames of 9--63min after injection of \[^11^C\]ORM-13070. (B) Mean regional brain radioactivity in the striatum (■) and cerebellum (▲) during baseline conditions (mean ± standard deviation, *n* = 9). (C) Correlation between striatal *BP* ~ND~ (simplified reference tissue model \[SRTM\], 33min) and mean striatal binding potential (*BP* ~ND~) estimates calculated by SRTM (63min) and interval method (IM) (*n* = 20). (D) Radiochromatogram of a plasma sample obtained 30min after i.v. injection of \[^11^C\]ORM-13070. SUV, standard uptake value.](ijnppy_pyu081_f0002){#F2}

Pretreatment with atipamezole was associated with dose-dependent decreases in striatal \[^11^C\]ORM-13070 binding, but did not affect tracer uptake in the cerebellum ([Figure 3A](#F3){ref-type="fig"} and [B](#F3){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). A constrained one-site binding hyperbole described the relationship between dose and striatal α~2C~-AR occupancy well (*R* ^2^ = 0.97), with an *ID* ~50~ of 16±3 μg/kg. Similarly, the relationship between atipamezole concentrations in plasma (mean of the values at 20--60min) and α~2C~-AR occupancy was also well described by a constrained one-site binding hyperbole (*R* ^2^ = 0.93), with an *IC* ~50~ of 3±1ng/mL.

###### 

Striatal *BP* ~ND~ and Cerebellar *V* ~T\ AUC~ Values During Baseline and After i.v. Administration of Atipamezole (2.5, 10, 50, and 500 µg/kg), Amphetamine (0.5 and 1.0mg/kg), or Atomoxetine (0.3 mg/kg) in Cynomolgus Monkeys.

  Day                     Monkey   Study      *BP* ~ND~   %Change   *V* ~T\ AUC~   %Change
  ----------------------- -------- ---------- ----------- --------- -------------- ---------
  1                       NHP1     Baseline   0.46                  3.9            
  Atipamezole 2.5 µg/kg   0.42     -9         4.1         6                        
  Atipamezole 10 µg/kg    0.26     -43        5.4         39                       
  2                       NHP2     Baseline   0.64                  5.2            
  Atipamezole 50 µg/kg    0.17     -73        5.0         -3                       
  Atipamezole 500 µg/kg   0.07     -89        5.1         -2                       
  3                       NHP2     Baseline   0.75                  4.4            
  Amphetamine 0.5mg/kg    0.49     -35        4.3         -2                       
  4                       NHP3     Baseline   0.51                  4.4            
  Amphetamine 0.5mg/kg    0.33     -35        4.6         4                        
  5                       NHP1     Baseline   0.55                  4.5            
  Amphetamine 1.0mg/kg    0.38     -31        4.3         -6                       
  6                       NHP2     Baseline   0.84                  4.3            
  Amphetamine 1.0mg/kg    0.42     -50        4.0         -6                       
  7                       NHP1     Baseline   0.70                  3.9            
  Atomoxetine 0.3 mg/kg   0.61     -13        4.6         16                       
  8                       NHP3     Baseline   0.68                  3.8            
  Atomoxetine 0.3 mg/kg   0.71     4          3.6         -4                       
  9                       NHP4     Baseline   0.72                  4.3            
  Baseline                0.73     1          4.8         12                       

*BP* ~ND~, binding potential; *V* ~T\ AUC~, surrogate distribution volume

![(A) Time activity course for regional radioactivity (SUV) in the striatum and cerebellum during baseline and pretreatment with atipamezole (500 µg/kg) before i.v. injection of \[^11^C\]ORM-13070 in a representative cynomolgus monkey. (B) Relative decrease in mean striatal binding potential as a function of atipamezole dose and atipamezole concentration in plasma. The lines represent a constrained one-site binding fit.](ijnppy_pyu081_f0003){#F3}

Pretreatment with amphetamine was associated with dose-dependent decreases in the striatal *BP* ~ND~ estimates ([Table 1](#T1){ref-type="table"}). The decrease in striatal *BP* ~ND~ was 35% after 0.5mg/kg (*n* = 2) and 40% after 1.0mg/kg (*n* = 2) of amphetamine. Pretreatment with atomoxetine (0.3mg/kg) did not markedly influence the striatal binding of \[^11^C\]ORM-13070 (-4%, *n* = 2; [Table 1](#T1){ref-type="table"}). In the final test-retest experiment, the striatal *BP* ~ND~ estimates were almost identical, at 0.72 and 0.73 ([Table 1](#T1){ref-type="table"}).

Rat Brain Microdialysis {#s18}
-----------------------

Baseline striatal NE concentrations were consistently lower than DA concentrations (nM: 0.09±0.03 vs 1.39±0.23; *p* \< 0.0001). Concentrations of both neurotransmitters were significantly higher under isoflurane anesthesia (DA: *p* = 0.008; NE: *p* = 0.015; [Figure 4A](#F4){ref-type="fig"}). Administration of amphetamine (0.3mg/kg, s.c.) produced significant increases in NE and DA concentrations in anesthetized and freely-moving rat striatum ([Figure 4B](#F4){ref-type="fig"} and [C](#F4){ref-type="fig"}). In freely-moving rats (*n* = 4--6), the absolute increase in DA (peak change ≈ 3.4nM) far exceeded the change in NE (peak change ≈ 0.2nM), but if expressed in terms of percent of baseline, the effect on NE was greater ([Figure 4D](#F4){ref-type="fig"}). In anesthetized rats (*n* = 6--8), the absolute increase in DA (peak change ≈ 7.1nM) also far exceeded the change in NE (peak change ≈ 0.4nM). Administration of atomoxetine (1mg/kg, i.p.; *n* = 5) to freely-moving rats produced almost two-fold increases in striatal NE (*p* = 0.037) with no significant effects on DA (*p* = 0.312; [Figure 4D](#F4){ref-type="fig"}).

![(A) Extracellular concentrations of norepinephrine (NE) and dopamine (DA) in the striatum of awake or anesthetized rats. The effects of amphetamine (0.3mg/kg s.c., administered at t = 0) on concentrations of NE (B) and DA (C). The mean effects of amphetamine (Amph; 0.3mg/kg s.c.) and atomoxetine (Atom; 1mg/kg i.p.) on NE and DA in freely-moving rats expressed as percent of basal concentrations (D). Data are means ± standard error of the mean, \**p* \< 0.05. Veh, vehicle.](ijnppy_pyu081_f0004){#F4}

*In Vitro* Receptor Binding {#s19}
---------------------------

Atipamezole was bound with high affinity (*K* ~i~ \< 5nM) to all three α~2~-AR subtypes, while amphetamine and atomoxetine displayed low binding affinities (*K* ~i~ \> 1 µM; [Table 2](#T2){ref-type="table"}).

###### 

Results of *in vitro* receptor binding assay with recombinant human α~2~-AR subtypes and the subtype non-selective antagonist radioligand \[^3^H\]RS 79948-197.

  *K* ~i~ \[nM\] (CI)   α~2A~-AR            α~2B~-AR            α~2C~-AR
  --------------------- ------------------- ------------------- --------------------
  Amphetamine           1244 (986--1570)    1578 (1148--2170)   4919 (3889--6221)
  Atipamezole           1.1 (0.91--1.3)     2.2 (1.8--2.6)      4.9 (3.8--6.4)
  Atomoxetine           4626 (3780--5661)   1387 (1046--1840)   8735 (7048--10830)

AR, adrenoceptor; CI, 95% confidence interval of the *K* ~i~ estimate; *K* ~*i*~, binding affinity estimate.

Discussion {#s20}
==========

We explored the use of the novel α~2C~-AR antagonist PET radioligand \[^11^C\]ORM-13070 for measurement of changes in synaptic NE concentrations in the brain. *In vivo* PET measurements in monkeys demonstrated that administration of amphetamine caused dose-dependent decreases in striatal \[^11^C\]ORM-13070 binding. *Ex vivo* experiments in rats provided support for this notion. Striatal microdialysis confirmed amphetamine-induced elevations in extracellular NE, both in awake and in isoflurane-anesthetized rats. Taken together, these results indicate that \[^11^C\]ORM-13070 may be useful as a tool to investigate alterations in synaptic NE concentrations *in vivo*.

The need for methods to monitor changes in synaptic NE in the living human brain has been recognized in clinical neuroscience. With post-mortem autoradiography, we demonstrated that the regional pattern of \[^11^C\]ORM-13070 binding is conserved across species, and is consistent with the known α~2C~-AR distribution in mammalian brains ([@CIT0018]; [@CIT0012]). Validation of measurement of changes in synaptic NE concentrations using \[^11^C\]ORM-13070 in rodents and monkeys thus provides a cross-species translational method suitable for application in human subjects.

This is the first study to evaluate \[^11^C\]ORM-13070 binding in non-human primates. After injection of \[^11^C\]ORM-13070, the radioactivity concentration was high in the striatum and the cerebellar radioactivity concentration was low, in agreement with the cerebellum having a negligible density of α~2C~-ARs. The lack of specific binding in the cerebellum was confirmed in experiments with atipamezole pretreatment, as atipamezole did not affect cerebellar tracer uptake ([Figure 3A](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). The relatively fast receptor kinetics and adequate specific binding ratios further support that \[^11^C\]ORM-13070 may be suitable for quantitative assessment of α~2C~-ARs in the non-human primate brain.

After injection of \[^11^C\]ORM-13070, two radioactive metabolites were observed in monkey blood. A similar pattern of metabolites has been seen in rodent studies, and M1 but not M2 could be detected in the rat brain ([@CIT0002]). The molecular identities of M1 and M2 have not been resolved, in spite of efforts involving stable isotopes and mass spectroscopy, but they have been inferred to be very small molecular weight fragments with no affinity for α~2C~-ARs ([@CIT0002]). Additional studies are thus required to further understand the potential influence of M1 on the estimates of non-specific \[^11^C\]ORM-13070 binding in brain during the later phase of data acquisition.

PET measurements, combined with amphetamine administration, have previously been used to investigate changes in synaptic DA concentrations in humans ([@CIT0025]). Amphetamine, however, elevates synaptic monoamine concentrations in a non-selective manner, in particular NE and DA, predominantly through the redistribution of catecholamines from synaptic vesicles to the cytosol and the induction of reverse transport of transmitters through plasma membrane uptake carriers ([@CIT0042]). In the current monkey study, amphetamine dose-dependently decreased striatal *BP* ~ND~ estimates, with a reduction of about 40% in *BP* ~ND~ after 1.0mg/kg. A smaller dose of amphetamine (0.3mg/kg) caused a trend-level decrease in \[^11^C\]ORM-13070 binding in rats (20%, *p* = 0.10), which was in accordance with the anticipated decrease based on the results in monkeys. Thus, amphetamine dose-dependently reduced striatal \[^11^C\]ORM-13070 binding, which was consistent across species and in line with amphetamine-enhanced synaptic NE concentrations.

Microdialysis experiments were performed in rats to further elucidate the amphetamine-induced changes in \[^11^C\]ORM-13070 binding. Striatal extracellular DA concentrations were 15-fold higher than those of NE at baseline, and anesthesia increased the extracellular concentrations of NE and DA, as already reported by others ([@CIT0008]; [@CIT0001]). Importantly, the amphetamine-induced relative increases in NE and DA were similar in awake and anesthetized rats. The use of anesthesia in the non-human primate PET experiments can thus be considered not to significantly confound the evaluation of the suitability of \[^11^C\]ORM-13070 binding to reflect synaptic NE levels.

When attempting to monitor drug-induced alterations of synaptic neurotransmitter concentrations with a competition binding approach, it is important to consider a possible direct effect of the challenge compound on radioligand binding to the target receptor. Amphetamine was found to have very low α~2C~-AR affinity (*K* ~i~ ≈ 5 µM), suggesting that the reduction observed in \[^11^C\]ORM-13070 binding is likely to represent an indirect effect, e.g. changes in monoamine concentrations at the target receptors.

The amphetamine-induced decreases observed in \[^11^C\]ORM-13070 binding in monkey striatum were larger than those previously reported for the D~2~ receptor radioligand \[^11^C\]raclopride (23% after 1.0mg/kg of amphetamine; Seneca, [@CIT0038]). In microdialysis experiments in rat striatum, the relative amphetamine-evoked increase in NE concentrations was greater than the DA increase. Still, DA also binds to α~2C~-ARs, albeit with five-fold lower affinity than NE ([@CIT0034]). From the current study, it cannot be ruled out that the decreased \[^11^C\]ORM-13070 binding was partly related to increased DA, and future studies are required to further understand a potential contribution of DA to the amphetamine effect.

A possible limitation of using \[^11^C\]ORM-13070 is that α~2C~-ARs are predominantly expressed in the striatum, a brain region with relatively scant NE innervation. Striatal NE projections have, however, been demonstrated in the nucleus accumbens, using immunohistochemical staining of dopamine beta-hydroxylase in rats ([@CIT0004]; [@CIT0010]) and autoradiography of NET in monkeys (Smith, [@CIT0040]). Interestingly, a previous PET study in pigs, performed with the subtype non-selective α~2~-AR tracer \[^11^C\]yohimbine, also demonstrated substantial amphetamine-evoked reductions in tracer uptake in the striatum, as well as in other brain regions in which NE predominates over DA ([@CIT0024]). These studies provide support for the notion that the observed reduction in \[^11^C\]ORM-13070 binding after amphetamine could relate to elevated extracellular concentrations of NE.

In an attempt to selectively elevate synaptic NE concentrations, we performed experiments with the potent NET inhibitor atomoxetine. Administration of atomoxetine to freely-moving rats increased striatal extracellular NE concentrations almost two-fold, without significant effects on DA, which agrees with previous results ([@CIT0007]). In preliminary PET studies in two monkeys, atomoxetine did not markedly modify the striatal binding of \[^11^C\]ORM-13070: the observed changes were -13% and +4%. This is not surprising, since atomoxetine increased extracellular NE to a smaller extent than amphetamine. However, insufficient NET occupancy in the monkey brain can be excluded as an explanation because this dose of atomoxetine almost saturates the NET capacity (Seneca, [@CIT0038]; [@CIT0043]). Future studies with atomoxetine should thus be performed in a larger number of subjects. Preliminary results in humans indicate that atomoxetine, as well as sympathetic activation by ketamine and the cold pressor test ([@CIT0030]) reduce \[^11^C\]ORM-13070 binding by 10--15% in human subjects ([@CIT0500]; [@CIT0037]).

It should be noted that α~2C~-ARs are currently considered as potential drug targets for several central nervous system disorders, including schizophrenia and Alzheimer's disease ([@CIT0035]). A number of established antipsychotics, in particular clozapine, have relative high α~2C~-AR affinity ([@CIT0022]). The possible interaction of DA with α~2C~-ARs may also be clinically relevant and needs further evaluation. Characterization of the DA contribution in the effect of amphetamine on \[^11^C\]ORM-13070 binding in dopamine beta-hydroxylase knockout mice that are deficient of NE may help determine the extent to which DA is a co-transmitter of striatal α~2C~-ARs.

We evaluated the use of the novel α~2C~-AR antagonist PET radioligand \[^11^C\]ORM-13070 for measurement of changes in synaptic NE concentrations. Amphetamine caused dose-dependent decreases in \[^11^C\]ORM-13070 binding in rat and monkey striatum. It is concluded that \[^11^C\]ORM-13070 may be a useful tool for investigations on alterations in synaptic NE concentrations *in vivo*. Future studies are required to further understand a potential contribution of DA to the amphetamine-evoked effect.
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